DALLAS, Feb. 26, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Hemispherx Biopharma Inc. (AMEX:HEB). The report includes financial, comparative and investment analysis, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.investorsoup.com/lp/HEB
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup">www.twitter.com/investorsoup
Hemispherx Biopharma, Inc. (HEB) is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's products include Ampligen® and Alferon N Injection®. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS. Alferon N Injection is an indicator for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is under early stage development targeting influenza and viral diseases.
Message Board Search for HEB: http://www.boardcentral.com/boards/HEB
In the report, the analyst notes:
"HEB net loss was approximately $2,435,000 for the three months ended September 30, 2009, and was $980,000 or 29% less when compared to the same period in 2008. This decrease in loss for these three months was primarily due to the following expense elements:
- Production/Cost of Goods Sold decreased approximately $53,000 or 27%.
- Research and Development costs were down approximately $421,000 or 26%.
- General and Administrative expenses decreased approximately $511,000 or 31%.
"Revenues from the Ampligen cost recovery program increased $8,000 or 47% for the quarter in 2009 with approximately the same number of patients participating in the program. HEB has no Alferon N Injection product to commercially sell at this time and all revenue was generated from the Ampligen cost recovery clinical treatment programs."
To read the entire report visit: http://www.investorsoup.com/lp/HEB
See what investors say about HEB at penny stock forum
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit www.InvestorSoup.com/">http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither InvestorSoup nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.